What’s new in IMHA?
Immune‐mediated haemolytic anaemia (IMHA) is an important cause of morbidity and mortality in dogs. IMHA also occurs in cats, although less commonly. IMHA is considered secondary when it can be attributed to an underlying disease, and as primary (idiopathic) if no cause is found. Eliminating diseases that cause IMHA may attenuate or stop immune‐mediated erythrocyte destruction, and adverse consequences of long‐term immunosuppressive treatment can be avoided. Infections, cancer, drugs, vaccines, and inflammatory processes may be underlying causes of IMHA. Treatment with various immunosuppressive and antithrombotic drugs has been described anecdotally and in previous studies, but little consensus exists among veterinarians as to the optimal regimen to employ and maintain after diagnosis of the disease. In this webinar, Scott will discuss the most effective ways to diagnose IMHA and consolidate your knowledge of the pathophysiology of the disease. We will also review the most recent treatment options, especially when the steroids don’t work.
Meet the speakers
Scott Kilpatrick
Director, Internal Medicine Specialist
already purchased this webinar? login to your vtx account for access
login